Abbreviations: UBM = unrelated bone marrow; UCB = unrelated cord blood. The slash (/) is used to separate possible alleles in the order of frequency.
Pretransplant donor-specific anti-HLA antibodies (DSAs) have been shown to be important factors responsible for graft rejection in allogeneic stem cell transplantation (SCT). [1] [2] [3] Previous studies referring to the deleterious effects of DSAs in allogeneic SCT suggested that the presence of DSAs in serum samples from pretransplant patients, not generated during the posttransplantation period, indicate a risk of graft rejection. We present the first reported case of graft rejection associated with anti-HLA DQA1/DQB1 antibody generation after SCT from an HLA-DRB1-, HLA-DQA1-and HLA-DQB1-mismatched unrelated donor.
A 4-year-old boy with mucopolysaccharidosis type II (MPS-II) was referred to the Tokai University Hospital to receive unrelated bone marrow transplantation (UBMT) to prevent neurological deterioration. 4 HLA typing performed before UBMT revealed matches for HLA-A, HLA-B and HLA-C 6/6, and a mismatch for HLA-DRB1 (Table 1) . HLA-DQA1 and HLA-DQB1 typing were not performed. Before referral, the patient was treated with a weekly infusion of idursulfatase, and no blood transfusion was performed. The conditioning procedure comprised busulfan (17.6 mg/kg), cyclophosphamide (200 mg/kg) and anti-thymocyte globulin (5 mg/kg; Genzyme, Cambridge, MA, USA). Prophylaxis against GvHD was performed by short-term administration of methotrexate (MTX; 15 mg/m 2 per day on day 1 and 10 mg/m 2 per day on post-transplantation days 3, 6 and 11) and tacrolimus (0.03 mg/kg per day continuous intravenous infusion). Granulocyte CSF at a dose of 7 μg/kg was administered from post-transplantation day 5 until a neutrophil count 41.5 × 10 9 /L was achieved. On day 0, the patient's peripheral blood findings showed profound myelosuppression with a white blood cell count of 0.075 × 10 9 /L, and 3.1 × 10 8 /kg bone marrow nucleated cells (2.6 × 10 6 /kg bone marrow CD34-positive cells) were infused via a central venous catheter. Blood products were not transfused before graft infusion. A neutrophil count 40.5 × 10 9 /L and a reticulocyte count 420 × 10 9 /L were achieved at days 16 and 19, respectively. On day 25, the white blood cell count increased to 5.6 × 10 9 /L and the reticulocyte count reached 5.4%. Donor cell engraftment was examined by the STR method, and 93.8% donor-type cells were detected by using bone marrow cells collected on day 28. The white blood cell count began to decrease from day 33, and the proportion of donor-derived CD3 + cells was reduced to 8.9% in the peripheral blood at day 39, finally resulting in complete graft rejection. Secondary SCT was planned by using unrelated cord blood with matched HLA-6 of eight alleles and mismatched HLA-A and HLA-DRB1 (Table 1 ). Before determining the cord blood unit, the anti-HLA antibody in the patient's serum was analyzed at posttransplantation day 61, and 30 of anti-HLA class I antibodies and 16 of anti-HLA class II antibodies (Table 2) showed a mean fluorescence intensity (MFI) 41000. The HLA-DQA1 and HLA-DQB1 typings were not provided by the cord blood bank, and all other anti-HLA antibodies did not crossreact with the selected cord blood. Rituximab (100 mg/m 2 ) was administered for desensitization 7 days before starting conditioning. 9 /L were achieved on days 17 and 22, respectively. STR analysis of bone marrow cells showed 97.2% donor-type cells at 14 days, 100% at 31 days and 100% at 59 days after transplantation. Acute GvHD grade II developed at posttransplantation day 10 and was successfully treated with 1 mg/kg prednisolone. At post-transplantation month 38, the patient is alive with 100% Karnofsky scale and 100% donor chimerism.
To clarify the mechanism of graft failure after the first SCT in our study patient, we studied the presence of DSAs and performed typing for the corresponding donor/recipient HLA alleles (DQA and DQB). Anti-HLA antibody was tested with the patient's serum samples collected and cryopreserved at 1 day before the first SCT and at 41 days after the first SCT. Then, we compared the results of this test to the results of anti-HLA antibody assay performed before secondary SCT (at post-transplantation day 61). The patient's serum samples were screened for class I (HLA-A, HLA-B and HLA-C) and class II HLA antibodies (HLA-DR, HLA-DP and HLA-DQ) by using the LAB Screen Mixed Kit (One Lambda, Canoga Park, CA, USA). Results with a cutoff value 43.0 were considered positive. Positive samples were further examined for specificity by using a panel of fluorescent beads coated with single HLA antigen preparation (LABScreen Single-Antigen, One Lambda).
The screening test results for anti-class I/II HLA antibodies with serum samples collected 1 day before transplantation were negative; however, they became positive and consistently intensified in the serum samples collected +41 and +61 days (Table 2 ). However, the main DSA in this patient was considered as the anti-HLA antibody against HLA-DQB1*03:01 because HLA-DQB1*03:01 is the major allele of HLA-DQ7 and is linked by haplotype to a number of DQA1 genes, produced in cis-haplotype form. Although anti-class I HLA antibodies also became strongly positive after transplantation, they were not involved in the mechanism of graft rejection because HLA-A, HLA-B and HLA-C were identical between the patient and the first donor. Eight blood products (seven platelet concentrates and one red cell concentrate) and four doses of gamma globulin were administered from the day of transplantation until posttransplantation day 41. The anti-HLA antibody levels in all the blood donors were similarly measured and found to be negative. Anti-HLA antibodies were detected with lower MFI values in the same gamma globulin lot; however, even the antibody against HLA-C*17:01, with the highest MFI, was not detected in the patient's serum sample collected after transplantation.
Oclega et al. 5 studied DSAs during the post-transplantation period and reported that none of the patients generated DSAs at 30 days, 100 days and 1 year after transplantation in a group of 30 allo-SCT recipients from HLA-mismatched unrelated donors. Our patient did not possess DSAs immediately before SCT and started to generate DSAs at 41 days after transplantation; the MFI of DSA continued to increase until 61 days. In parallel with the emergence of DSAs, pancytopenia developed, followed by late graft rejection. The synchronism between DSAs and graft rejection might represent the cause and effect. Because passive transfer of anti-HLA antibodies by transfusion of blood products 6 or gamma globulin 7 was denied, we can conclude that the DSAs in this patient was generated by the residual host cells. The second SCT was performed by using reduced-intensity conditioning and HLA-DRB1-mismatched cord blood as the stem cell source. The success in the second SCT may be credited to both the selection of the cord blood in which HLA was nonreactive with the generated anti-HLA antibodies and the use of rituximab before conditioning; 8 hence, the main causative factor of graft rejection in the first SCT seemed to be DSAs emerging post transplantation and not HLA-DRB1 mismatch.
The expressions of the HLA-DQA1 and HLA-DQB1 antigens are considerably low in comparison with that of other HLA antigens, 9 and its role in SCT is not completely understood. Thus, HLA-DQA1 and HLA-DQB1 typings are not considered essential for selecting cord blood. However, in renal transplantation, de novo class II antibodies were almost exclusively directed against HLA-DQ specificities, 10 and the time of generation of antibody was earliest with the anti-HLA-DQ antibody than with other HLA antibodies. Moreover, HLA antibodies have been detected in nonalloimmunized healthy men. Among Mexican donors with HLAclass II specificities, 20.5% possessed antibodies to HLA-DPA1*02:01 and DPB1*01:01, and 10.8% to HLA-DQA1*05:03 and DQB1*03:01. 6 Recently, Yamamoto et al. 11 reported that patients with anti-HLA antibodies against HLA-C, HLA-DP, HLA-DQ and HLA-DRB3/4/5 possessed lower engraftment rates in HLA-mismatched unrelated cord blood recipients. Thus, HLA-DQ antigens possibly possessed high antigen-presenting activities in humans.
The clinically relevant MFIs of DSAs may differ according to the amount of corresponding antigens expressed on the surface of donor cells and/or the donor cell source. Several studies on the relationships between DSAs and graft rejection used different definitions of DSA positivity. Although treatments were performed to decrease the DSA level, the presence of DSAs (MFI45000) before transplantation has been reported to be a significant risk factor for graft failure after unmanipulated haploidentical SCT. 8 Among 10 patients with high-MFI DSAs (MFI410 000), only two, including one who was receiving plasmapheresis and rituximab to decrease the level of DSAs, had successful engraftment, whereas eight had graft failure. 2, 8, 12 Therefore, the MFIs of DSAs must be cautiously interpreted; DSAs with MFI410 000 are high-risk factors for graft rejection.
Although the phenomenon was reported in only one case in our study, we demonstrated that high-MFI DSAs possibly responsible for graft rejection could be generated even after myeloablative SCT. Therefore, DSA levels should be examined even after SCT in case of development of unexplained pancytopenia. The first donor possessed the underlined alleles.
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